Voyager Therapeutics (NASDAQ:VYGR) Trading Down 1.6%

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report)'s stock price traded down 1.6% during trading on Friday . The stock traded as low as $8.62 and last traded at $8.64. 72,492 shares were traded during mid-day trading, a decline of 92% from the average session volume of 945,859 shares. The stock had previously closed at $8.78.

Analyst Ratings Changes

Several equities analysts have commented on the stock. HC Wainwright assumed coverage on shares of Voyager Therapeutics in a research note on Tuesday, March 19th. They issued a "buy" rating and a $30.00 price target for the company. Wells Fargo & Company upgraded shares of Voyager Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their price target for the stock from $9.00 to $14.00 in a research note on Tuesday, January 2nd. Citigroup assumed coverage on shares of Voyager Therapeutics in a research note on Thursday, March 7th. They issued a "buy" rating and a $16.00 price target for the company. Guggenheim initiated coverage on shares of Voyager Therapeutics in a research note on Tuesday, March 26th. They issued a "buy" rating and a $22.00 price target for the company. Finally, StockNews.com raised Voyager Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, March 9th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $19.33.

Voyager Therapeutics Stock Down 4.0 %

The stock has a fifty day moving average of $8.74 and a 200-day moving average of $7.94. The stock has a market cap of $457.75 million, a PE ratio of 2.80 and a beta of 0.96.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its quarterly earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $1.84. The firm had revenue of $90.06 million for the quarter, compared to analyst estimates of $4.95 million. Voyager Therapeutics had a return on equity of 63.89% and a net margin of 52.93%. Equities research analysts forecast that Voyager Therapeutics, Inc. will post -1.64 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Voyager Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Citigroup Inc. acquired a new stake in shares of Voyager Therapeutics during the 1st quarter valued at approximately $186,000. BlackRock Inc. lifted its position in shares of Voyager Therapeutics by 10.6% during the 1st quarter. BlackRock Inc. now owns 514,155 shares of the company's stock valued at $3,919,000 after acquiring an additional 49,319 shares during the period. Lazard Asset Management LLC lifted its position in shares of Voyager Therapeutics by 144.7% during the 1st quarter. Lazard Asset Management LLC now owns 17,678 shares of the company's stock valued at $134,000 after acquiring an additional 10,455 shares during the period. Charles Schwab Investment Management Inc. acquired a new stake in shares of Voyager Therapeutics during the 1st quarter valued at approximately $122,000. Finally, Northern Trust Corp lifted its position in shares of Voyager Therapeutics by 2.2% during the 1st quarter. Northern Trust Corp now owns 79,119 shares of the company's stock valued at $603,000 after acquiring an additional 1,683 shares during the period. Institutional investors and hedge funds own 48.03% of the company's stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.